Samuel George A. III 4

4 · Lineage Cell Therapeutics, Inc. · Filed Feb 13, 2026

AI-generated summary of this filing

Updated Feb 14, 2026

Lineage (LCTX) GC Samuel George Receives 6,075 RSU Shares; 2,502 Withheld

What Happened

Samuel George A. III, General Counsel and Secretary of Lineage Cell Therapeutics (LCTX), had 6,075 restricted stock units (RSUs vest) convert into 6,075 common shares on February 11, 2026.
To satisfy statutory tax withholding, the company withheld 2,502 of those shares at a withholding value of $1.80 per share (total $4,504). No shares were sold on the open market in connection with this transaction.

Key Details

Transaction date: February 11, 2026; Form 4 filed February 13, 2026 (timely within the two-business-day window).
Vesting/conversion: 6,075 RSUs converted one-for-one into common shares (reported as derivative conversion/exercise).
Tax withholding: 2,502 shares withheld at $1.80/share for $4,504 (reported as disposition to cover tax liability).
Shares owned after the transaction: not disclosed in the filing.
Relevant footnotes: these RSUs were part of a 24,303-RSU grant made Feb 11, 2022 that vests ~25% each year through 2026; the filing notes the withholding was done by the issuer and no open-market sale occurred.

Context

This is a routine vesting/tax-withholding event, not an open-market sale or purchase. For RSU vesting, companies often withhold shares to cover taxes (a tax-withholding disposition) rather than selling shares on the market. Such transactions reflect compensation vesting rather than a signal of insider buying or selling intent.

Form 4

Period: 2026-02-11

General Counsel and Secretary

Transactions

Exercise/Conversion
Common Shares
[F1][F2]
2026-02-11+6,075→ 33,565 total
Tax Payment
Common Shares
[F3][F2]
2026-02-11$1.80/sh−2,502$4,504→ 31,063 total
Exercise/Conversion
Restricted Stock Units
[F4]
2026-02-11−6,075→ 0 total
Exercise: $0.00→ Common Shares (6,075 underlying)

Footnotes (4)

[F1]Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis.
[F2]Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options.
[F3]Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 6,075 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction
[F4]The Reporting Person was granted 24,303 RSUs on February 11, 2022, that vested with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026.

Signature

/s/ George A. Samuel III|2026-02-13

1 file